Skip to Content

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

The ALPINE study is the first study to demonstrate a superior Progression-Free Survival (PFS) and safety profile of zanubrutinib compared to ibrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL).

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top